Human VEGFR3/Flt-4 DuoSet ELISA DY349B-05 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman VEGFR3/Flt-4 DuoSet ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $450.00Supplier Page View Company Product Page
Catalog NumberDY349B-05
Quantity1 Kit (for 5 Plates)
ApplicationsELISA
Detection Range93.80 - 6000 pg/mL
ReactivityHuman
Detection TargetVEGFR3/Flt-4
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
NCBI Full Gene Namefms related receptor tyrosine kinase 4
NCBI Gene AliasesCHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL, VEGFR-3, VEGFR3

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) CIRCULATING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR)-3, A PRO-LYMPHANGIOGENIC AND PRO-ANGIOGENIC MEDIATOR, IS DECREASED IN PREECLAMPSIAInternational Journal of Gynecology & ObstetricsJanuary 1, 2025Ana C. Palei, Julyane N. S. Kaihara, Ricardo C. Cavalli, Valeria C. Sandrimusing a commercially available Duoset enzyme-linked immunosorbent assay (ELISA) kit (Catalog number: DY349B-05, R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions. Assay range was 93.8

(2) Matrix stiffness primes lymphatic tube formation directed by vascular endothelial growth factor‐CThe FASEB JournalMay 1, 2021Laura Alderfer, Elizabeth Russo, Adriana Archilla, Brian Coe, Donny Hanjaya‐Putracells from the hydrogels and cell lysates were analyzed using a Human VEGFR-3/Flt4 ELISA (R&D Systems, DY349B-05) kit according to the manufacturer’s protocol. Transmission Electron Microscopy Human LECs cultured

(3) Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factorsThe Journal of infectionJanuary 1, 2017Kumar NP, Moideen K, Sivakumar S, Menon PA, Viswanathan V, Kornfeld H, Babu S.

(4) Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary TuberculosisPloS oneJanuary 1, 2016Kumar NP, Banurekha VV, Nair D, Babu S.

(5) Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation modelThe American journal of pathologyNovember 1, 2012Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L.

(6) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinomaClinical cancer research : an official journal of the American Association for Cancer ResearchApril 15, 2012Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J, SHARP Investigators Study Group..

(7) Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinibJournal of translational medicineJuly 25, 2011Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, et al.

(8) Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in miceMolecular therapy : the journal of the American Society of Gene TherapyFebruary 1, 2009Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, et al.

(9) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaJournal of clinical oncology : official journal of the American Society of Clinical OncologyAugust 1, 2008Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, et al.

(10) Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in KoreansThe Journal of investigative dermatologyJune 1, 2008Lee JH, Cho EY, Namkung JH, Kim E, Kim S, Shin ES, Lee JE, Yang JM.

(11) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneJournal of clinical oncology : official journal of the American Society of Clinical OncologyApril 10, 2008Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al.

(12) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapyJournal of clinical oncology : official journal of the American Society of Clinical OncologyOctober 20, 2007Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, et al.

Be the First to Write a Review!

VEGFR3/Flt-4 ELISA

Human sVEGFR3/Flt-4 DuoSet ELISA

Human VEGFR3/Flt-4 DuoSet ELISA from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (12)

Reviews

Human VEGFR3/Flt-4 DuoSet ELISA from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map